Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Predicting survival after whole-brain irradiation for cerebral metastases from prostate cancer

Anticancer Res. 2014 Aug;34(8):4357-60.

Anticancer Res. 2014 Aug;34(8):4357-60.



Prostate cancer patients represent a small minority of those presenting with cerebral metastases. Knowledge about overall survival (OS) contributes to individualization of treatment concepts. In this study an OS score was created for patients receiving whole-brain irradiation (WBI) for cerebral metastases from prostate cancer.


Of six variables, four were significantly associated with OS: performance status, time from diagnosis of prostate cancer to WBI, number of cerebral lesions, extracranial metastases.


Six-month OS rates of the four variables (in %, divided by 10) were added. The addition resulted in scores of 1 to 19 points. Six-month OS rates were 0% for <15 points and 100% for ≥ 15 points (p<0.001).


An OS score was generated specifically for patients with cerebral lesions from prostate cancer. For patients with <15 points, a short WBI regimen (5x4 Gy) should be used, for patients with ≥ 15 points a longer regimen seems appropriate.

Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.


Cerebral metastases; overall survival; predictive score; prostate cancer; whole-brain irradiation

Comment from Henk van der Poel: How to treat men with brain-metastasized disease based on overall survival scores? This score may help to decide on the extent of radiotherapy based on life-expectancy after 6 months.


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre


URO ONCO is made possible by an unrestricted educational grant from:

The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.

The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views.